A rather stale PharmaLive story has PWC picking up another legacy Schering-Plough
cast-off alumna. But not just any alumna. She was head of global compliance at legacy Schering-Plough.
So, did PriceWaterhouseCoopers ask Ms. Queisser about this, prior to hiring her? To be clear, I am certain she is a fine executive -- just as I am certain that compliance problems were rampant at legacy Schering-Plough long before she arrived in 2007. This one, more than most, though, smells like pharma run-amok. What was she doing about it (since 2007)? These are -- even today -- important questions, as New Merck will (once again) ultimately have to belly-up and pay Fred's bar-tab, here.
[H/T Ed, at Pharmalot.] Here's a snippet from the linked story:
. . . .PricewaterhouseCoopers LLP today announced that Lori Queisser, former chief compliance officer at Schering-Plough Corporation and Eli Lilly, is working with PricewaterhouseCoopers Governance, Risk and Compliance practice as a senior advisor to the firm’s pharmaceutical and life sciences clients. . . .
Most recently, Ms. Queisser was senior vice president, global compliance and business practices at Schering-Plough Corporation, a position she held since 2007. . . .
So, what went on in Vietnam, to ameliorate these practices, while you were at legacy Schering-Plough, Ms. Queisser? Training? Role-playing? The signing of adherence to global compliance standards statements? What, exactly? We would like to know -- we, the ex-shareholders -- of legacy Schering-Plough. We, who lost our lives'-savings.